Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy

NCT03194971 · View on ClinicalTrials.gov ↗

Study Summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Conditions Studied

Interventions

  • OTHER Tumor samples from patients treated with TTFields at initial diagnosis.
  • DEVICE Tumor samples from patients treated with TTFields at tumor recurrence.

Study Locations (1)

Wisconsin

  • Froedtert & the Medical College of Wisconsin — Milwaukee

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-06-01
Est. Completion 2027-05-31

Sponsor

Medical College of Wisconsin

614 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03194971

The ClinicalTrials.gov registry entry for NCT03194971 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 614 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions — of which Tumor samples from patients treated with TTFields at initial diagnosis. is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03194971 reports 1 study location spanning 1 distinct geographic area — top geographies include Wisconsin. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03194971 about?

NCT03194971 is a clinical study titled "NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy". This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

What is the current status of trial NCT03194971?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2017-06-01. Estimated completion is 2027-05-31.

What conditions does trial NCT03194971 study?

This clinical trial studies the following conditions: Glioblastoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03194971?

The interventions under investigation include: Tumor samples from patients treated with TTFields at initial diagnosis. (OTHER), Tumor samples from patients treated with TTFields at tumor recurrence. (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03194971?

This trial is sponsored by Medical College of Wisconsin, which has 614 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03194971 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial